Latest Posters

This poster explores how advanced automation tools can address these challenges, enabling clinical biobanks to improve compliance, optimize space and streamline operations for diverse sample sets.

This poster explores how a novel polymerase variant provides the tools needed to reduce double-stranded RNA (dsRNA) byproducts during manufacturing, ensuring the tolerability, safety and potency of mRNA vaccines and therapeutics.

This poster details a resin-based approach employing immobilized caprylic acid, to effectively eliminate high aggregate levels along with host cell protein residues, for enhanced monoclonal antibody purification.

This poster explores state-of-the-art nucleic acid detection, the critical steps and the advantages of this approach.

To meet these needs, we developed scalable capture and polishing chromatography steps for recombinant AAV. Here we highlight the polishing step.

The industry has adopted standardized methods for the production and purification of rAAV, streamlining processes for greater efficiency. However, high titers are crucial for meeting demand and cutting costs for therapies that require large doses or have wide patient bases.

Obtaining enough synthetic mRNA for clinical use has long been a hurdle in treating conditions like cancer and infectious diseases.. Current mRNA production methods involve complex purification steps and chemicals, limiting large-scale manufacturing.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

This poster highlights several methods by which the downstream purification of viral vectors can be improved using chromatography methods to analyse and purify multiple AAV serotypes.

Recent advancements in affinity technology now support more robust and efficient Protein A chromatography. Hence, the latest Protein A solutions can enhance productivity, yield and accelerate products to market.